Amgen Inc. (AMGN)

US — Healthcare Sector
Peers: GILD  PFE  SNY  MRK  ISRG  BMY  DHR  GSK  BSX  SYK 

Automate Your Wheel Strategy on AMGN

With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AMGN
  • Rev/Share 64.8792
  • Book/Share 13.8067
  • PB 21.6424
  • Debt/Equity 7.5665
  • CurrentRatio 1.3056
  • ROIC 0.1044

 

  • MktCap 160867904697.0
  • FreeCF/Share 19.7119
  • PFCF 15.1691
  • PE 24.2876
  • Debt/Assets 0.6394
  • DivYield 0.0314
  • ROE 0.9792

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 3
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed AMGN Raymond James -- Market Perform -- -- Sept. 3, 2025
Resumed AMGN Guggenheim -- Neutral -- $288 May 20, 2025
Resumed AMGN Cantor Fitzgerald -- Neutral -- $305 April 22, 2025
Resumed AMGN BofA Securities -- Underperform -- $256 Dec. 10, 2024
Initiation AMGN Bernstein -- Outperform -- $380 Oct. 17, 2024
Downgrade AMGN Truist Buy Hold $320 $333 Oct. 14, 2024
Initiation AMGN Cantor Fitzgerald -- Overweight -- $405 Sept. 27, 2024

News

5 Best Dividend Stocks in the Nasdaq Composite
ADP, AMGN, EXC, KMB, PEP
Published: October 20, 2025 by: 24/7 Wall Street
Sentiment: Positive

What's the first thing that springs to mind when someone mentions the Nasdaq Composite?

Read More
image for news 5 Best Dividend Stocks in the Nasdaq Composite
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
AMGN
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Why Amgen (AMGN) Could Beat Earnings Estimates Again
AMGN
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More
image for news Why Amgen (AMGN) Could Beat Earnings Estimates Again
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
AMGN
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
AMGN
Published: October 07, 2025 by: CNBC
Sentiment: Positive

Amgen is the latest drugmaker to sell certain drugs directly to consumers amid pressure from President Donald Trump. Meanwhile, Dr. Oz talks GLP-1s for obesity.

Read More
image for news Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
AMGN
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive

AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.

Read More
image for news Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
My Top 5 Biotech Stocks Big Pharma Could Buy Next
ABBV, ALVO, AMGN, ARKG, AZN, BIIB, BMY, CSLLY, GILD, GRFS, GSK, IBB, INCY, JNJ, KMDA, LEGN, LLY, MRK, NVS, PFE, PHAT, RDY, REGN, RHHBY, SDZNY
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Read More
image for news My Top 5 Biotech Stocks Big Pharma Could Buy Next
Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts
AMGN
Published: October 06, 2025 by: WSJ
Sentiment: Negative

The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.

Read More
image for news Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts
Here's Why Amgen (AMGN) is a Strong Value Stock
AMGN
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Here's Why Amgen (AMGN) is a Strong Value Stock
Amgen to sell cholesterol drug at 60% discount direct to US consumers
AMGN
Published: October 06, 2025 by: Reuters
Sentiment: Neutral

Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to U.S. political pressure to lower drug prices.

Read More
image for news Amgen to sell cholesterol drug at 60% discount direct to US consumers
Amgen Shares Cross Above 200 DMA
AMGN
Published: October 01, 2025 by: Forbes
Sentiment: Positive

In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.

Read More
image for news Amgen Shares Cross Above 200 DMA
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
AMGN, UTHR
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
AMGN, CI
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Goldman Sachs Sees 4 Rate Cuts by Next Summer: 5 High-Yield Dividend Winners
AMGN, CMCSA, DUK, MRK, T
Published: September 26, 2025 by: 24/7 Wall Street
Sentiment: Positive

Investors love dividend stocks because they offer a significant income stream and have massive total return potential.

Read More
image for news Goldman Sachs Sees 4 Rate Cuts by Next Summer: 5 High-Yield Dividend Winners
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
AMGN
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
AMGN
Published: September 26, 2025 by: PRNewsWire
Sentiment: Neutral

THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

Read More
image for news AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
Amgen: Imdelltra Could Be The Next Game Changer
AMGN
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Positive

Despite the political noise coming out of the White House over efforts to lower drug prices, Amgen Inc.'s oncology franchise has continued to deliver strong performance since the start of 2025. So, AMGN's sales of Imdelltra, which is rapidly capturing the lung cancer therapeutics market, reached $134 million in Q2 2025, an impressive 1016.7% increase year-over-year. Also, thanks to the synergy effects from the acquisition of Horizon, as well as growing demand for Blincyto, AMGN's gross profit margin reached 70.9%, 9.5% higher than in Q2 2024.

Read More
image for news Amgen: Imdelltra Could Be The Next Game Changer
Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?
AMGN
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Read More
image for news Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
AMGN
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Amgen (AMGN) is a Top Value Stock for the Long-Term
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
AMGN, VKTX
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

Read More
image for news AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
AMGN
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read More
image for news Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
AMGN
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral

Amgen Inc. (NASDAQ:AMGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Peter Griffith - Executive VP & CFO Kave Niksefat - Senior Vice President of Global Marketing & Access Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.

Read More
image for news Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
AMGN
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral

Amgen Inc. (NASDAQ:AMGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capparelli Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst So we have Paul Burton. He's the Chief Medical Officer of the company; and dabbing for the first time, Adam Elinoff, the new IR at Amgen.

Read More
image for news Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Investing in the Age of Longevity: Silver Economy Stocks in Focus
ABBV, AMGN, DXCM, SYK
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.

Read More
image for news Investing in the Age of Longevity: Silver Economy Stocks in Focus
Here's Why Amgen (AMGN) is a Strong Value Stock
AMGN
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Amgen (AMGN) is a Strong Value Stock
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
AMGN, AS, COST, DASH, MRK, MU
Published: August 27, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee debate the latest Calls of the Day.

Read More
image for news Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
AMGN
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.

Read More
image for news AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
AMGN
Published: August 25, 2025 by: PRNewsWire
Sentiment: Neutral

THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.

Read More
image for news REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
AMGN
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
AMGN, JNJ
Published: August 14, 2025 by: Seeking Alpha
Sentiment: Positive

Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.

Read More
image for news Back To Basics: Why I Favor Amgen Over Johnson & Johnson

About Amgen Inc. (AMGN)

  • IPO Date 1983-06-17
  • Website https://www.amgen.com
  • Industry Drug Manufacturers - General
  • CEO Robert A. Bradway
  • Employees 28000

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.